Clinical Investigation of Benign Asbestos Pleural Effusion

• Main Authors: Nobukazu Fujimoto, Kenichi Gemba, Keisuke Aoe, Katsuya Kato, Takako Yokoyama, Ikuji Usami, Kazuo Onishi, Keiichi Mizuhashi, Toshikazu Yusa, Takumi Kishimoto
• Format: Article
• Language: English
• Published: Hindawi Limited 2015-01-01
• Series: Pulmonary Medicine
• Online Access: http://dx.doi.org/10.1155/2015/416179

There is no detailed information about benign asbestos pleural effusion (BAPE). The aim of the study was to clarify the clinical features of BAPE. The criteria of enrolled patients were as follows: (1) history of asbestos exposure; (2) presence of pleural effusion determined by chest X-ray, CT, and thoracentesis; and (3) the absence of other causes of effusion. Clinical information was retrospectively analysed and the radiological images were reviewed. There were 110 BAPE patients between 1991 and 2012. All were males and the median age at diagnosis was 74 years. The median duration of asbestos exposure and period of latency for disease onset of BAPE were 31 and 48 years, respectively. Mean values of hyaluronic acid, adenosine deaminase, and carcinoembryonic antigen in the pleural fluid were 39,840 ng/mL, 23.9 IU/L, and 1.8 ng/mL, respectively. Pleural plaques were detected in 98 cases (89.1%). Asbestosis was present in 6 (5.5%) cases, rounded atelectasis was detected in 41 (37.3%) cases, and diffuse pleural thickening (DPT) was detected in 30 (27.3%) cases. One case developed lung cancer (LC) before and after BAPE. None of the cases developed malignant pleural mesothelioma (MPM) during the follow-up.